Medicus Pharma Ltd
MDCXHealthcare·Drug Manufacturers - General·Canada·Nano·NASD·Nov 11 • 3:57 PM ET
1.64-0.19 (-10.38%)
2026-11-12 00:40 CET
Market cap
0.43 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-36.63 USD m
Free cash flow, TTM
-27.38 USD m
EPS diluted, TTM
-48.55
P/E
-
Price
MDCX against its 20, 50 and 200-day averages2050200miss
98.7% under the 52-week high of 127.50 on 17 Nov 2025. 52-week low 1.63 on 11 Nov 2026. Last 15 sessions, 71.8% high to low
Volume 0.48× normal · the line is the 50-bar volume average
Profile
MDCX52-week range, 0% of the way up
1.70127.5
Medicus Pharma Ltd. is a biotech life sciences company, which focuses on accelerating the clinical development programs of novel and disruptive therapeutic assets. It develops a product, SkinJectTM, with an indication for basal cell carcinoma. The company was founded on April 30, 2008 and is headquartered in Toronto, Canada.
| Employees | 16 |
|---|---|
| IPO | Jan 26, 2024 |
| Beta | -0.01 |
| ATR, 14d | 0.43 |
| Rel volume | 0.48 |
| Short float | 34.48% |
| Insider own | 22.91% |
| Inst own | 26.90% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 3.15M |
| Enterprise Value | 14.51M |
| Income | -36.63M |
| Sales | 0.00M |
| Book/sh | -4.01 |
| Cash/sh | 1.84 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 16 |
| IPO | Jan 26, 2024 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | - |
| P/C | 0.89 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 0.65 |
| Current Ratio | 0.65 |
| Debt/Eq | - |
| LT Debt/Eq | - |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -48.55 |
|---|---|
| EPS next Y | -15.11 |
| EPS next Q | -4.44 |
| EPS this Y | 77.32% |
| EPS next Y | 51.37% |
| EPS next 5Y | 53.77% |
| EPS past 3/5Y | -129.98% - |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 37.61% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 79.62% |
| Sales Q/Q | - |
| Earnings | Nov 09 AMC |
| EPS/Sales Surpr. | -97.06% - |
Ownership
| Insider Own | 22.91% |
|---|---|
| Insider Trans | 0.00% |
| Inst Own | 26.90% |
| Inst Trans | - |
| ROA | -364.14% |
| ROE | -5705.59% |
| ROIC | -1008.42% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | -29.04% |
| SMA50 | -70.03% |
| SMA200 | -91.91% |
| Trades | - |
Technical
| Shs Outstand | 1.85M |
|---|---|
| Shs Float | 0.18M |
| Short Float | 34.48% |
| Short Ratio | 0.56 |
| Short Interest | 0.06M |
| 52W High | 127.50 -98.71% |
| 52W Low | 1.70 -3.53% |
| Volatility | 18.35% 14.51% |
| ATR (14) | 0.43 |
| RSI (14) | 18.31 |
| Beta | -0.01 |
| Rel Volume | 0.48 |
| Avg Volume | 111.20K |
| Volume | 53,486 |
Performance
| Perf Week | -12.77% |
|---|---|
| Perf Month | -50.00% |
| Perf Quarter | -90.73% |
| Perf Half Y | -89.75% |
| Perf YTD | -97.86% |
| Perf Year | -98.54% |
| Perf 3Y | - |
| Perf 5Y | - |
| Perf 10Y | - |
| Recom | 1.00 |
| Target Price | 121.67 |
| Prev Close | 1.83 |
| Price | 1.64 |
| Change % | -10.38% |
Analyst ratings
latest 1 of 1| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Today | Downgrade | BBrookline Capital Markets | Buy → Hold |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| VRCA | Verrica Pharmaceuticals Inc | 67.17M |
| MBRX | Moleculin Biotech Inc | 8.50M |
| PTHS | Pelthos Therapeutics Inc | 36.92M |
| SLGL | Sol-Gel Technologies Ltd | 207.57M |
| MIRA | Mira Pharmaceuticals Inc | 26.14M |
| IMNN | Imunon Inc | 4.04M |
| REPL | Replimune Group Inc | 2.06B |
| VERU | Veru Inc | 36.49M |
| SCYX | Scynexis Inc | 33.99M |
| CPIX | Cumberland Pharmaceuticals Inc | 91.70M |
News
latest 14 of 200- Medicus Pharma sharpens focus on Pfizer-licensed cancer drug CD228V, trims costs in Q3 (Proactive)
- Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement (ACCESSWIRE)
- Medicus Pharma Reports Third Quarter 2026 Financial Results and Provides Corporate Update (ACCESSWIRE)
- Medicus Pharma's Report Tests Cash Runway After 89% Collapse In Share Price (Earnings Whispers)
- Medicus Pharma to Present at BIO-Europe 2026 (GlobeNewswire)
- Medicus Pharma to Host Third Quarter 2026 Financial Performance and Business Update Call on November 9, 2026 (GlobeNewswire) -7.39%
- Medicus Pharma plans SPAC listing for SkinJect unit at $135 million valuation (Proactive)
- Medicus Pharma Announces Proposed SkinJect Business Combination and Concurrent Financing (GlobeNewswire)
- MARKETS LIVE: Wall Street soars following historic Democratic midterm victory; FTSE follows suit (Proactive)
- Medicus Pharma CEO to present precision oncology progress at global biotech conferences (Proactive)
- Medicus Pharma to Present at BioFuture and Global Biotechnology Summit (GlobeNewswire)
- Medicus Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
- Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing (InvestorsHub) -36.39%
- Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances (Proactive)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q3 | 2026-11-09 | -11.640 | -5.907 | -10.500 | 0.00 | 0.00 | 3 |
| 2026Q2 | 2026-08-12 | -10.500 | -6.375 | -10.500 | 0.00 | 0.00 | 4 |
| 2026Q1 | 2026-05-14 | -15.500 | -9.600 | -11.157 | 0.00 | 0.00 | 4 |
| 2025Q4 | 2026-03-26 | -29.680 | -3.500 | -21.460 | 0.00 | - | 2 |
| 2025Q3 | 2025-11-21 | -56.000 | -47.250 | -40.798 | 0.00 | 0.00 | 4 |
| 2025Q2 | 2025-08-12 | -21.500 | -12.500 | -15.612 | 0.00 | 0.00 | 3 |
| 2025Q1 | 2025-05-14 | -21.000 | -12.335 | -14.526 | 0.00 | 0.00 | 3 |
| 2024Q4 | 2025-02-26 | -7.000 | -13.695 | -6.882 | 0.00 | 0.00 | 3 |
| 2024Q3 | 2024-11-27 | -14.010 | -11.025 | -11.401 | 0.00 | 0.00 | 1 |
| 2026Q4 | - | - | -4.440 | - | - | - | 3 |
| 2027Q1 | - | - | -0.200 | - | - | - | 1 |
| 2027Q2 | - | - | -0.200 | - | - | - | 1 |
| 2027Q3 | - | - | -0.210 | - | - | - | 1 |
| 2027Q4 | - | - | -0.210 | - | - | - | 1 |
| 2028Q1 | - | - | 0.560 | - | - | 15.03 | 1 |
| 2028Q2 | - | - | 0.580 | - | - | 15.66 | 1 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2023FY | -89.685 | -91.570 | -24.378 | 0.00 | 0.00 |
| 2024FY | -58.000 | -53.240 | -34.455 | 0.00 | 0.00 |
| 2025FY | -137 | -90.750 | -137 | 0.00 | 0.00 |
| 2026FY | - | -31.070 | - | - | 0.00 |
| 2027FY | - | -15.110 | - | - | 0.00 |
| 2028FY | - | -13.537 | - | - | 0.00 |
| 2029FY | - | 7.197 | - | - | 73.67 |
| 2030FY | - | 17.180 | - | - | 127.71 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q4 | S | 2026-08-13 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | S | 2026-05-15 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | S | 2026-04-20 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | S | 2025-11-21 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | S | 2025-11-11 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | S | 2025-11-10 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q4 | R | 2026-11-10 | 1 | 1 | 0 | -0.82 | -0.82 | -0.82 |
| 2026Q4 | R | 2026-10-15 | 1 | 1 | 0 | -0.82 | -0.82 | -0.82 |
| 2026Q4 | R | 2026-09-09 | 1 | 1 | 0 | -1.00 | -1.00 | -1.00 |
| 2026Q4 | R | 2026-08-13 | 1 | 1 | 0 | -2.00 | -2.00 | -2.00 |
| 2026Q4 | R | 2026-06-03 | 1 | 1 | 0 | -4.00 | -4.00 | -4.00 |
| 2026Q4 | R | 2026-05-26 | 1 | 1 | 0 | -5.00 | -5.00 | -5.00 |
| 2026Q4 | R | 2026-05-15 | 2 | 1 | 1 | -4.05 | -5.00 | -3.10 |
| 2026Q4 | R | 2026-05-05 | 2 | 1 | 1 | -4.05 | -5.00 | -3.10 |
Estimate history
| EPS, annual | -8.048 | -24.378 | -34.455 | -97.889 | -48.5541 | ||||
|---|---|---|---|---|---|---|---|---|---|
| Period | 2022 | 2023 | 2024 | 2025 | TTM | ||||
| EPS, quarterly | -11.401 | -6.882 | -14.526 | -15.612 | -40.798 | -21.46 | -11.157 | -7.621 | -8.315 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | ||||
| Period | 2022 | 2023 | 2024 | 2025 | TTM | ||||
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
| Shares, annual | 0.162 | 0.162 | 0.236 | 0.504 | 1.85 | ||||
| Period | 2022 | 2023 | 2024 | 2025 | MRQ | ||||
| Shares, quarterly | 0.217 | 0.236 | 0.268 | 0.319 | 0.419 | 0.504 | 0.8 | 1.203 | 1.85 |
| Period | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY |
|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 23.33 | 18.35 | 8.16 | 3.50 | 0.75 |
| Research and Development | 8.77 | 5.53 | 2.58 | 0.14 | 0.50 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -23.33 | -18.35 | -8.16 | -3.50 | -0.75 |
| Interest Expense | 1.13 | 0.14 | - | 0.43 | 0.40 |
| Unusual Expense | 7.32 | 6.87 | 0.00 | 0.00 | -0.30 |
| Net Income Before Taxes | -31.74 | -25.37 | -8.14 | -3.94 | -1.30 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -31.74 | -25.37 | -8.14 | -3.94 | -1.30 |
| Net Income From Continuing Operations | -31.70 | -25.37 | -8.14 | -3.94 | -1.30 |
| Net Income | -36.63 | -33.84 | -8.14 | -3.94 | -1.30 |
| EPS (Recurring) | -24.16 | -83.97 | -34.46 | -24.38 | -9.34 |
| EPS (Basic, Before Extraordinaries) | -48.55 | -97.89 | -34.45 | -24.38 | -8.05 |
| EPS (Diluted) | -48.55 | -97.89 | -34.45 | -24.38 | -8.05 |
| EBITDA | -23.33 | -18.35 | -8.16 | -3.50 | -0.75 |
| Non-Operating Income (Expense) | 0.04 | 0.00 | 0.02 | 0.00 | -0.44 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 1.85 | 1.08 | 0.52 | 0.07 | 0.00 |
| Shares Outstanding | 1.85 | 0.50 | 0.24 | 0.16 | 0.16 |
| Market Capitalization | 0.43 | 0.43 | 28.71 | 26.68 | - |
Income statement, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 3.19 | 8.29 | 6.27 | 5.59 | 4.87 | 4.34 | 3.57 | 1.74 |
| Research and Development | 1.39 | 3.55 | 1.97 | 1.86 | 1.22 | 1.04 | 1.40 | 0.98 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -3.19 | -8.29 | -6.27 | -5.59 | -4.87 | -4.34 | -3.57 | -1.74 |
| Interest Expense | 0.51 | 0.15 | 0.27 | 0.20 | - | - | - | - |
| Unusual Expense | 7.14 | 0.00 | 0.09 | 0.09 | 6.74 | 0.14 | 0.00 | 0.00 |
| Net Income Before Taxes | -10.84 | -8.44 | -6.59 | -5.87 | -11.60 | -4.46 | -3.56 | -1.63 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -10.84 | -8.44 | -6.59 | -5.87 | -11.60 | -4.46 | -3.56 | -1.63 |
| Net Income From Continuing Operations | -10.84 | -8.39 | -6.59 | -5.87 | -11.60 | -4.46 | -3.56 | -1.63 |
| Net Income | -10.84 | -8.39 | -6.59 | -10.81 | -15.20 | -4.46 | -3.56 | -1.63 |
| EPS (Recurring) | -4.48 | -7.62 | -11.05 | -21.34 | -28.13 | -15.26 | -14.53 | -6.88 |
| EPS (Basic, Before Extraordinaries) | -8.31 | -7.62 | -11.16 | -21.46 | -40.80 | -15.61 | -14.53 | -6.88 |
| EPS (Diluted) | -8.31 | -7.62 | -11.16 | -21.46 | -40.80 | -15.61 | -14.53 | -6.88 |
| EBITDA | -3.19 | -8.29 | -6.27 | -5.59 | -4.87 | -4.34 | -3.57 | - |
| Non-Operating Income (Expense) | 0.00 | 0.00 | 0.04 | 0.00 | 0.01 | 0.03 | 0.02 | 0.05 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.09 | 1.02 | 0.44 | 0.31 | 0.62 | 0.00 | 0.08 | 0.09 |
| Shares Outstanding | 1.85 | 1.20 | 0.80 | 0.50 | 0.42 | 0.32 | 0.27 | 0.24 |
| Market Capitalization | 0.43 | 26.85 | 18.36 | 38.52 | 48.55 | 47.65 | 49.91 | 28.71 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY |
|---|---|---|---|---|
| Cash & Short Term Investments | 6.35 | 2.90 | 1.30 | 0.20 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.79 | 0.84 | 0.13 | 0.01 |
| Total Current Assets | 7.14 | 3.74 | 1.44 | 0.21 |
| Net Property, Plant & Equipment | 0.12 | 0.19 | 0.00 | 0.00 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.07 | 0.00 | 0.00 | 0.00 |
| Total Assets | 7.34 | 3.93 | 1.44 | 0.21 |
| Short Term Debt Incl. Current Port. of LT Debt | 3.93 | 0.08 | 0.00 | 8.46 |
| Accounts Payable | 0.00 | 0.00 | 0.00 | 0.11 |
| Other Current Liabilities | 3.32 | 1.52 | 0.59 | 0.64 |
| Total Current Liabilities | 7.25 | 1.60 | 0.59 | 9.21 |
| Long Term Debt | 0.06 | 0.14 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 7.31 | 1.75 | 0.59 | 9.21 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -0.05 | 2.18 | 0.84 | -9.00 |
| Total Shareholders Equity | -0.05 | 2.18 | 0.84 | -9.00 |
| Accumulated Minority Interest | 0.08 | 0.00 | 0.00 | 0.00 |
| Total Equity | 0.03 | 2.18 | 0.84 | -9.00 |
| Total Liabilities & Stockholders Equity | 7.34 | 3.93 | 1.44 | 0.21 |
| Book Value Per Share | -0.10 | 9.22 | 5.22 | -55.73 |
| Tangible Book Value Per Share | -0.10 | 9.22 | 5.22 | -55.73 |
| Full-Time Employees | 16 | 12 | - | - |
| Price to Book Ratio | -0.46 | 13.17 | 10.32 | - |
| Return on Assets | -450.30 | -303.73 | -478.97 | - |
| Return on Equity | -2,381.47 | -538.82 | - | - |
| Return on Invested Capital | -188,460.85 | -350.57 | -467.17 | - |
| Quick Ratio | 0.99 | 2.33 | 2.42 | 0.02 |
| Current Ratio | 0.99 | 2.33 | 2.42 | 0.02 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY |
|---|---|---|---|---|---|
| Net Income | -31.27 | -25.37 | -8.14 | -3.94 | -1.30 |
| Other Funds (Non Cash) | 4.23 | 8.66 | 0.64 | 0.51 | 0.55 |
| Funds from Operations | -27.04 | -16.71 | -7.50 | -3.43 | -0.75 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -0.34 | 0.41 | 0.02 | 0.35 | -0.06 |
| Cash from Operating Activities | -27.38 | -16.30 | -7.48 | -3.08 | -0.81 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | - | - |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.04 | -3.31 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.04 | -3.31 | 0.00 | 0.00 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 21.04 | 19.75 | 5.49 | 0.00 | 0.00 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 21.04 | 19.75 | 5.49 | 0.00 | 0.00 |
| Proceedsfrom Stock Options | 17.48 | 5.56 | 5.49 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 9.39 | 3.10 | 3.78 | 0.37 | 0.84 |
| Change in Long Term Debt | 10.71 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 15.71 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -5.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 3.79 | 0.12 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | - |
| Cash from Financing Activities | 30.44 | 22.86 | 9.26 | 4.16 | 0.96 |
| Exchange Rate Effect | - | -0.00 | - | - | - |
| Net Change in Cash | 3.13 | 3.25 | 1.78 | 1.08 | 0.15 |
| Free Cash Flow | -27.38 | -16.30 | -7.48 | -3.08 | -0.81 |
| Preferred Dividends (Cash Flow) | - | - | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 3.54 | 10.70 | 4.56 | 6.35 | 6.23 | 7.09 |
| Short Term Receivables | 0.44 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 0.51 | 1.27 | 0.66 | 0.79 | 0.80 | 0.97 |
| Total Current Assets | 4.49 | 11.97 | 5.22 | 7.14 | 7.03 | 8.06 |
| Net Property, Plant & Equipment | 0.06 | 0.08 | 0.10 | 0.12 | 0.14 | 0.16 |
| Total Investments and Advances | 5.69 | 7.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.53 |
| Total Assets | 10.24 | 19.11 | 5.32 | 7.34 | 7.17 | 8.75 |
| Short Term Debt Incl. Current Port. of LT Debt | 4.30 | 2.56 | 1.78 | 3.93 | 4.98 | 3.54 |
| Accounts Payable | 1.50 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Liabilities | 1.06 | 5.08 | 2.48 | 3.32 | 2.68 | 2.73 |
| Total Current Liabilities | 6.86 | 7.64 | 4.27 | 7.25 | 7.66 | 6.26 |
| Long Term Debt | 10.56 | 12.69 | 0.03 | 0.06 | 0.09 | 0.10 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.20 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 17.63 | 20.33 | 4.30 | 7.31 | 7.75 | 6.37 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | -7.42 | -1.24 | 0.95 | -0.05 | -0.65 | 2.38 |
| Total Shareholders Equity | -7.42 | -1.24 | 0.95 | -0.05 | -0.65 | 2.38 |
| Accumulated Minority Interest | 0.03 | 0.03 | 0.07 | 0.08 | 0.08 | 0.00 |
| Total Equity | -7.39 | -1.22 | 1.02 | 0.03 | -0.58 | 2.38 |
| Total Liabilities & Stockholders Equity | 10.24 | 19.11 | 5.32 | 7.34 | 7.17 | 8.75 |
| Book Value Per Share | -4.01 | -1.03 | 1.19 | -0.10 | -1.56 | 7.47 |
| Tangible Book Value Per Share | -4.01 | -1.03 | 1.19 | -0.10 | -1.56 | 7.47 |
| Full-Time Employees | - | - | - | 16 | - | - |
| Price to Book Ratio | -0.46 | -21.60 | 19.32 | -781.65 | -74.22 | 20.01 |
| Return on Assets | -364.14 | -233.02 | -616.59 | -452.51 | -372.58 | -155.79 |
| Return on Equity | - | -5,705.59 | -2,336.00 | -2,393.14 | -2,200.89 | -332.95 |
| Return on Invested Capital | -344.99 | -73.33 | -670.86 | -43,609.31 | - | -179.50 |
| Quick Ratio | 0.65 | 1.57 | 1.22 | 0.99 | 0.92 | 1.29 |
| Current Ratio | 0.65 | 1.57 | 1.22 | 0.99 | 0.92 | 1.29 |
Cash flow, quarterly
| Metric | 2026Q3 | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 |
|---|---|---|---|---|---|---|
| Net Income | -10.67 | -8.38 | -6.59 | -5.63 | -11.65 | -4.59 |
| Other Funds (Non Cash) | 1.45 | 1.37 | 0.83 | 0.58 | 7.67 | 0.33 |
| Funds from Operations | -9.22 | -7.01 | -5.77 | -5.04 | -3.98 | -4.26 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -2.04 | 1.99 | -0.74 | 0.45 | -0.97 | 0.21 |
| Cash from Operating Activities | -11.26 | -5.01 | -6.51 | -4.59 | -4.94 | -4.05 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.04 | -3.35 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | 0.00 | 0.00 | 0.00 | 0.04 | -3.35 | 0.00 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | - | - | 0.00 |
| Change in Capital Stock | 3.26 | 4.62 | 7.30 | 5.86 | 6.16 | 5.14 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 3.26 | 4.62 | 7.30 | 5.86 | 6.16 | 5.14 |
| Proceedsfrom Stock Options | 3.26 | 4.62 | 7.30 | 2.30 | -3.79 | 4.43 |
| Issuance or Reduction of Debt, Net | -0.74 | 13.77 | -2.32 | -1.31 | 1.21 | 3.21 |
| Change in Long Term Debt | 10.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 15.71 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | -5.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.20 |
| Other Financing Activities Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.22 | -0.20 |
| Cash from Financing Activities | 2.52 | 18.40 | 4.98 | 4.54 | 7.59 | 8.15 |
| Exchange Rate Effect | -0.03 | 0.20 | -0.14 | - | - | - |
| Net Change in Cash | -8.77 | 13.58 | -1.68 | -0.01 | -0.71 | 4.10 |
| Free Cash Flow | -11.26 | -5.01 | -6.51 | -4.59 | -4.94 | -4.05 |
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 34.48% | 0.1M | 0.2M | 108.12K |
| 2026-10-15 | 24.24% | 0.0M | 0.2M | 102.40K |
| 2026-09-30 | 41.99% | 0.1M | 0.2M | 87.35K |
| 2026-09-15 | 56.93% | 0.1M | 0.2M | 83.38K |
| 2026-08-31 | 32.64% | 0.1M | 0.2M | 34.85K |
| 2026-08-14 | 27.12% | 0.1M | 0.2M | 39.63K |
| 2026-07-31 | 29.26% | 0.1M | 0.2M | 42.89K |
| 2026-07-15 | 27.62% | 0.1M | 0.2M | 65.66K |
| 2026-06-30 | 10.21% | 0.0M | 0.2M | 80.47K |
| 2026-06-15 | 18.83% | 0.0M | 0.2M | 75.94K |
| 2026-05-29 | 31.06% | 0.1M | 0.2M | 135.05K |
| 2026-05-15 | 22.83% | 0.0M | 0.2M | 128.28K |
| 2026-04-30 | 18.34% | 0.0M | 0.2M | 122.50K |
| 2026-04-15 | 13.21% | 0.0M | 0.2M | 96.40K |
| 2026-03-31 | 23.82% | 0.0M | 0.2M | 77.30K |
| 2026-03-13 | 42.53% | 0.1M | 0.2M | 73.08K |
| 2026-02-27 | 10.89% | 0.0M | 0.2M | 7.75K |
| 2026-02-13 | 12.46% | 0.0M | 0.2M | 7.03K |
| 2026-01-30 | 14.03% | 0.0M | 0.2M | 6.14K |
| 2026-01-15 | 11.28% | 0.0M | 0.2M | 6.42K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-09 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions. | SEC | |
| 2026-11-06 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions. | SEC | |
| 2026-11-06 | 424B3 | SEC | ||
| 2026-11-06 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-09-30 | SEC |
| 2026-11-04 | 425 | Filing under Securities Act Rule 425 of certain prospectuses and communications in connection with business combination transactions. | SEC | |
| 2026-11-04 | 8-K | Current report | 2026-11-04 | SEC |
| 2026-10-30 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-12-02 | SEC |
| 2026-10-26 | 424B3 | SEC | ||
| 2026-10-23 | 8-K | Current report | 2026-10-20 | SEC |
| 2026-10-19 | PRE 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-12-02 | SEC |
| 2026-10-16 | 424B3 | SEC | ||
| 2026-10-16 | 8-K | Current report | 2026-10-12 | SEC |
| 2026-10-16 | SCHEDULE 13G/A | SEC | ||
| 2026-10-07 | 424B3 | SEC | ||
| 2026-10-07 | 8-K | Current report | 2026-10-07 | SEC |
| 2026-09-14 | 424B3 | SEC | ||
| 2026-09-14 | 8-K | Current report | 2026-09-11 | SEC |
| 2026-09-14 | SCHEDULE 13D | SEC | ||
| 2026-09-11 | 8-K | Current report | 2026-09-04 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-08 | 4 | Statement of changes in beneficial ownership of securities | 2026-09-04 | SEC |
| 2026-09-03 | 424B3 | SEC | ||
| 2026-09-03 | 8-K | Current report | 2026-09-02 | SEC |
| 2026-08-13 | 424B3 | SEC | ||
| 2026-08-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-06-04 | 424B3 | SEC | ||
| 2026-06-04 | 8-K | Current report | 2026-06-03 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| Interchange Capital Partners, LLC | 17.98% |
| JANE STREET GROUP, LLC | 2.82% |
| XTX Topco Ltd | 2.06% |
| Private Advisor Group, LLC | 1.95% |
| Sterling Investment Advisors, Ltd. | 0.85% |
| UBS Group AG | 0.69% |
| COMMONWEALTH EQUITY SERVICES, LLC | 0.63% |
| May Hill Capital, LLC | 0.43% |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.27% |
| STIFEL FINANCIAL CORP | 0.25% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 0.03% |
| Blackstone Alternative Multi-Strategy Fund | -0.06% |
OakChart. MDCX. Cached 15 minutes.
Some panels did not load: insider.